Loading clinical trials...
Loading clinical trials...
The purpose of this study is designed to examine the effects of Selegiline Transdermal System and behavioral intervention in smoking cessation as compared to behavioral intervention alone.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Collaborators
NCT07466875 · Nicotine Dependence, Nicotine Withdrawal, and more
NCT01036581 · Drug Abuse, Nicotine Dependence
NCT06295757 · Tobacco Use, Cigarette Smoking, and more
NCT07040566 · E-cigarette Use, Vaping, and more
NCT06534047 · Tobacco Use Disorder, Psychiatric Disorder, and more
Department of Public & Community Health
College Park, Maryland
Robert Wood Johnson Med School-Tobacco Dep Program
New Brunswick, New Jersey
Tri-State Tobacco and Alcohol Research Center
Cincinnati, Ohio
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions